胰高血糖素样肽1类似物对伴超重或肥胖初发2型糖尿病患者的疗效  

Therapeutic effect of glucagon-like peptide 1 analogue on overweight or obese patients with newly diagnosed type 2 diabetes

作　　者：曲建昌[1] 李丽[1] 赵蕾[1] 王彤[1] 祝开思[1] Qu Jianchang Li Li Zhao Lei Wang Tong Zhu Kaisi(Department of Endocrinology, the 305 Hospital of People′s Liberation Army, Beijing 100017, China)

机构地区：[1]解放军第三0五医院内分泌科,北京100017

出　　处：《中国医药》2017年第7期1012-1014,共3页China Medicine

摘　　要：目的 评价胰高血糖素样肽1（GLP-1）类似物利拉鲁肽对于伴超重或肥胖初发2型糖尿病患者的疗效。方法 选取2011年12月至2016年10月解放军第三〇五医院的初发2型糖尿病患者60例（体重指数≥23 kg/m2），完全随机分为对照组和观察组，各30例。对照组服用二甲双胍，观察组在对照组基础上加用利拉鲁肽注射液，连续治疗24周。比较2组治疗前及治疗24周后的体重指数、空腹血糖、糖化血红蛋白、总胆固醇、三酰甘油、低密度脂蛋白胆固醇（LDL-C）、高密度脂蛋白胆固醇以及胰岛素抵抗指数（HOMA-IR）。结果 治疗24周后，对照组体重指数、空腹血糖、糖化血红蛋白、三酰甘油、HOMA-IR均较治疗前明显下降［（25.4±2.3）kg/m2比（27.3±3.2）kg/m^2、（9.3±2.8）mmol/L比（10.4±3.7）mmol/L、（7.3±0.6）%比（8.1±0.9）%、（2.0±0.6）mmol/L比（2.6±0.7）mmol/L、（10±4）比（12±5）］（均P＜0.05）；观察组体重指数、空腹血糖、糖化血红蛋白、总胆固醇、三酰甘油、LDL-C、HOMA-IR均较治疗前明显下降［（23.3±2.1）kg/m^2比（26.9±3.7）kg/m^2、（7.1±0.9）mmol/L比（10.1±1.2）mmol/L、（6.5±0.6）%比（8.3±1.3）%、（4.21±0.22）mmol/L比（5.60±0.55）mmol/L、（1.9±0.3）mmol/L比（2.5±0.5）mmol/L、（2.5±0.7）mmol/L比（3.0±0.8）mmol/L、（8±3）比（11±5）］（P＜0.05）；观察组体重指数、空腹血糖、糖化血红蛋白、总胆固醇、HOMA-IR明显低于对照组（均P＜0.05）。结论 利拉鲁肽联合二甲双胍治疗伴肥胖初发2型糖尿病能更好地控制血糖和血脂水平，改善胰岛素敏感度，减轻体质量。Objective To analyze the therapeutic effect of analog of glucagon-like peptide 1 analogue liraglutide on overweight or obese patients with newly diagnosed type 2 diabetes. Methods Sixty cases of newly diagnosed type 2 diabetes[body mass index≥23 kg/m2] were enrolled from December 2011 to October 2016 in the 305 hospital of People′s Liberation Army. The patients were randomly divided into control group and observation group, with 30 cases in each group. The control group had metformin and the observation had metformin combined with liraglutide injection for 24 weeks. Body mass index, fasting blood glucose, glycosylated hemoglobin, total cholesterol, triacylglycerol, low density lipoprotein cholesterol, high density lipoprotein cholesterol and insulin resistance index（HOMA-IR） were analyzed. Results After 24 weeks of treatment, body mass index, fasting blood glucose, glycosylated hemoglobin, triacylglycerol and HOMA-IR in control group decreased significantly compared to those before treatment[（25.4±2.3）kg/m^2 vs （27.3±3.2）kg/m^2, （9.3±2.8）mmol/L vs （10.4±3.7）mmol/L, （7.3±0.6）% vs （8.1±0.9）%, （2.0±0.6）mmol/L vs （2.6±0.7）mmol/L, （10±4） vs （12±5）]（P〈0.05）; body mass index, fasting blood glucose, glycosylated hemoglobin, total cholesterol, triacylglycerol, low density lipoprotein cholesterol and HOMA-IR in observation group decreased significantly compared to those before treatment[（23.3±2.1）kg/m^2 vs （26.9±3.7）kg/m2, （7.1±0.9）mmol/L vs （10.1±1.2）mmol/L, （6.5±0.6）% vs （8.3±1.3）%, （4.21±0.22）mmol/L vs （5.60±0.55）mmol/L, （1.9±0.3）mmol/L vs （2.5±0.5）mmol/L, （2.5±0.7）mmol/L vs （3.0±0.8）mmol/, （8±3） vs （11±5）]（P〈0.05 or P〈0.01）. Body mass index, fasting blood glucose, glycosylated hemoglobin, total cholesterol and HOMA-IR in observation group were significantly lower than those in control group after treatment（P〈0.05）. Conclusion Liraglutide combined with metformin treating obe

关 键 词：糖尿病 2型 胰高血糖素样肽1 利拉鲁肽 超重 肥胖症 

分 类 号：R587.1[医药卫生—内分泌]